Author

Sally A. Kinrade

Observed names: Kinrade, Sally, S. Kinrade, Sally Kinrade

Observed institution: GlaxoSmithKline (Australia)

ORCID: 0000-0001-8510-4455

Observed ORCID: 0000-0001-8510-4455

OpenAlex ID: A5012997004

A framework for the development of effective anti-metastatic agents

2018 · Robin L. Anderson, Theo Balasas, et al. · Nature Reviews Clinical Oncology · 341

A genome-wide scan provides evidence for loci influencing a severe heritable form of common migraine

2005 · R. A. Lea, D. R. Nyholt, et al. · Neurogenetics · 51

Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial

2019 · Janin Chandra, Wai-Ping Woo, et al. · PLoS ONE · 32

Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?

2023 · Klodeta Kura, Philip Milton, et al. · Philosophical Transactions of the Royal Society B Biological Sciences · 30

Evaluation of the Cardiac Safety of Long‐Acting Endectocide Moxidectin in a Randomized Concentration‐ QT Study

2018 · Sally A. Kinrade, Jay W. Mason, et al. · Clinical and Translational Science · 16

Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling

2021 · Martin Walker, Jonathan I D Hamley, et al. · Clinical Infectious Diseases · 8

An Updated Economic Assessment of Moxidectin Treatment Strategies for Onchocerciasis Elimination

2024 · Hugo C Turner, Klodeta Kura, et al. · Clinical Infectious Diseases · 7

The use of quantitative clinical pharmacology approaches to support moxidectin dosing recommendations in lactation

2024 · Nolan D. Wood, Danelle Smith, et al. · PLoS neglected tropical diseases · 6

Identification of a moxidectin dose for 4- to 11-year-old children to support registration and potential use for onchocerciasis elimination: results of an open-label pharmacokinetic and safety study

2025 · Nicholas O. Opoku, Felix Doe, et al. · Parasites & Vectors · 4

Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021–2023: results of screening for clinical trials of moxidectin versus ivermectin

2026 · Françoise N. Ngave, Deogratias U. Wonyarossi, et al. · Parasites & Vectors · 3

Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021–2023: results of screening for clinical trials of moxidectin versus ivermectin

2026 · Ngave, Françoise N., Wonyarossi, Deogratias U., et al. · Figshare

Additional file 1 of Onchocerca volvulus infection prevalence and intensity in Logo and Nyarambe Health Zones in Ituri, Democratic Republic of the Congo in 2010 and in 2021–2023: results of screening for clinical trials of moxidectin versus ivermectin

2026 · Ngave, Françoise N., Wonyarossi, Deogratias U., et al. · Figshare

Works count: 16

Citation count: 499

H-index: 7

I10-index: 5